CVS Health Corporation (CVS) has agreed to acquire the entire outstanding shares of Aetna for a total consideration of $77bn.
The shareholders of the target company will be paid $145 a share in cash and issued 0.8378 CVS shares for each Aetna share held. The target company shareholders will hold 22% of the merged company, while the remaining will be held by the acquirer company shareholders.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The transaction will integrate the expertise of CVS and Aetna to redefine consumer healthcare experience and build a healthcare platform for individuals.
NeuroSearch has announced its intention to be sold to a potential buyer in 2018.
Based in Denmark, NeuroSearch is a biotechnology company involved in developing pharmaceuticals for the treatment of diseases and disorders.
The firm plans for voluntary liquidation in case it does not secure a satisfactory bid.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe net proceeds of liquidation are intended to be distributed to the shareholders.
